Core Tablets Research Articles

An Integrative QbD Approach for the Development and Optimization of Controlled Release Compressed Coated Formulation of Water-Soluble Drugs

Controlled release dosage forms maintain regulated pharmacokinetic profile of drug substance within its therapeutic window by ensuring constant plasma concentrations. Controlled release formulations not only increase the therapeutic efficacy of drug substances but also reduce their dose-related side effects. Present investigation was conducted to develop, optimize, and validate compressed coated controlled release tablet formulation for highly water-soluble drug substances which have no rate-controlling factor towards its release from dosage form. Drug dispersed waxy core tablet, press coated within the swellable hydrophilic polymeric barrier layer, was developed and optimized via quality by design approach (QbD) using Box-Behnken design. The optimized formulation was characterized and validated using in vitro quality control parameters. Attributes identified under SUPAC guidelines, such as drug release rates at 30 min, 6 h, and 12 h, were considered as the critical quality attributes (CQAs) that significantly affected efficiency of the compressed coated controlled release tablets. CQAs screened using risk assessment and Pareto chart analyses were used for optimizing controlled release dosage form. Findings revealed that tablets containing drug to wax ratio of 1:1, hydrophilic swellable polymer concentration of 200 mg, and prepared using compression pressure of 6.5 kg/cm2 exhibited the highest desirability indices in terms of controlling the release rate of drug substance. Optimized formulation was also evaluated for swelling rate, erosion rate, and other post-compression parameters, including release kinetics. Fickian diffusion-based zero-order controlled release of BCS class I drug substance was achieved through the developed dosage form.

Visualising liquid transport through coated pharmaceutical tablets using Terahertz pulsed imaging

Dissolution of pharmaceutical tablets is a complex process, especially for coated tablets where layered structures form an additional barrier for liquid transport into the porous tablet matrix. A better understanding of the role of the coating structure in the mass transport processes that govern drug release, starting with the wetting of the coating layer by the dissolution medium, can benefit the formulation design and optimisation of the production. For this study, terahertz pulsed imaging was used to investigate how dissolution medium can penetrate coated tablets. In order to focus on the fundamental process, the model system for this proof-of-principle study consisted of tablet cores made from pure microcrystalline cellulose compacted to a defined porosity coated with Opadry II, a PVA-based immediate release coating blend. The coating was applied to a single side of flat-faced tablets using vacuum compression moulding. It was possible to resolve the hydration of the coating layer and the subsequent liquid ingress into the dry tablet core. The analysis revealed a discontinuity in density at the interface between coating and core, where coating polymer could enter the pore space at the immediate surface of the tablet cores during the coating process. This structure affected the liquid transport of the dissolution medium into the core. We found evidence for the formation of a gel layer upon hydration of the coating polymer. The porosity of the tablet core impacted the quality of coating and thus affected its dissolution performance (r = 0.6932 for the effective liquid penetration rate RPeff and the core porosity). This study established a methodology and can facilitate a more in-depth understanding of the role of coating on tablet dissolution.

Optimization of thin layers of coated turmeric extract (Curcuma longa L) tablets using a dipping method

Turmeric extracts have many benefits, such as an anti-oxidant, anti-inflammatory, and neuro-protector for dementia. The turmeric extracts can be prepared in the form of a thin layer of coated tablets through a dipping method using the dip coating and Simplex lattice design (SLD) methods. The quality of the thin layers of coated tablets is much related to the formulation in the coating process. This research aims to formulate and optimize the coating composition of HPMC, PEG-400, and dip time. Consequently, the TSLT meets the standard requirements. The core tablets were made by using the wet granulation method with the formulation of turmeric extract, erosol, lactose, gelatin, and aquades. Before the core tablets had been produced, the eligibility of granules was initially evaluated based on the standard requirements. Subsequently, the core tablets that meet the standard requirements were printed and replicated. The coating processes on core tablets were performed by dipping into the coating solution in the various duration of dipping times: 5, 30, and 60 seconds. The coating solution consists of HPMC, PEG-400, glycerine, sunset yellow, and distillate water. Then, produced TSLTs were evaluated based on the hardness, friability, and disintegration time. The best optimization process for the mixture of HPMC and PEG-400 indicates a more positive value of R (R = 0.2024).

A Fresh Look on Bergenin: Vision of Its Novel Drug Delivery Systems and Pharmacological Activities

Bergenin (BER), a key constituent of Bergenia crassifolia (Saxifragaceae), has gained extensive attention, owing to its array of pharmacological actions, including anti-infective, anti-cancer, anti-diabetic, neuroprotective, hepatoprotective, anti-urolithiatic, anti-hyperuricemic, and anti-bradykinin properties. Despite ever-intensifying support for its therapeutic features, the poor solubility, lower oral bioavailability, shorter half-life, and more intestinal pH degradation (pH 6.8 or above) of BER have puzzled researchers. To circumvent these pharmaceutical challenges, and to improve its therapeutic efficacy, newer approaches have been adopted by research scientists. Thus, a discussion of the existing literature may provide complete information about the advances in delivery strategies for enhancing its utility. This paper summarizes up-to-date works on the design and development of novel delivery carriers of this bioactive compound, such as phospholipid complexes, extended-release core tablets, prodrugs, herbal gels, polyherbal ointments, nanoparticles, and poly (lactic acid) polymers, with the objective of harnessing its full potential. This review also provides a deep insight into its bioactivities, along with mechanisms. Additionally, the physicochemical attributes, chemistry, and pharmacokinetics of BER are discussed herein. Hence, the comprehensive information documented in this review may introduce new avenues for research advancements of BER.

Press-Coated Aceclofenac Tablets for Pulsatile Drug Delivery: Formulation and In Vitro Evaluations.

The symptoms of some diseases show circadian rhythms, such as the morning stiffness associated with pain at the time of awakening in rheumatoid arthritis. Therapy for such diseases doesn’t require immediate release or sustained release of medicament. In such therapies, pulsatile drug release is more suitable with a programmed drug release. The purpose of this research was to formulate press-coated aceclofenac tablets for pulsatile drug delivery with a distinct delay time of no drug release and release of the drug when it is more likely desired (i.e., after 5 to 6 h). Immediate release core tablets having aceclofenac were formulated. Three formulations, F1, F2, and F3, were prepared with variable concentrations of sodium croscarmellose. Pre- and post-compression tests were performed on the core tablets. The selection criteria included the lowest disintegration time as a requirement of pulsatile drug delivery with an immediate release core and a delayed release coat. The disintegration times of F1, F2, and F3 were 120 s, 60 s, and 15 s, respectively. Therefore, the F3 formulation was selected as the core tablet formulation because it had the shortest disintegration time (15 s). The core tablets were press-coated using different polymers, such as HPMC K100M, Eudragit L100, HEC, and HPMC E5. The polymers were used in the coatings to hinder the release of the core for the desired time. 36 formulations of polymer were prepared: A1 to A10 had HPMC K100M and Avicel PH102; formulations B1 to B6 had HPMC K100M, Eudragit L100, and Avicel PH102; formulations C1 to C7 had HPMC K100M and hydroxyethyl cellulose; formulations D1 to D7 had HPMC K100M and HPMC E5; and formulations E1 to E6 had changed the coating weight of the formulation used for D6 (having HPMC K100M and HPMC E5 in the ratio of 12.5% to 87.5%). Evaluations of the press-coated tablets were carried out through thickness, hardness, weight variation, friability, and in vitro dissolution tests. These parameters concluded that the formulation of E6, having HPMC K100M and HPMC E5 in the ratio of 12.5% to 87.5% at 600 mg weight, was the most optimum formulation as it showed 3.5% drug release after 4 h, 21.4% drug release after 5 h, and 99.27% drug release after 6 h.

Development and pharmacokinetic evaluation of osmotically controlled drug delivery system of Valganciclovir HCl for potential application in the treatment of CMV retinitis.

Valganciclovir HCl (VGH) is the widely used drug for the treatment of cytomegalovirus (CMV) retinitis infection with an induction dose of 900mg per oral (p.o.) twice a day and a maintenance dose of 900mg (p.o.). This required dose of the drug also leads to multiple side effects due to repeated administration. The research was highlighted to develop, formulate, optimize, and evaluate single-core osmotic pump (SCOP) tablet of VGH with the dose of 450mg to reduce dosing frequency and associated side effects. The decrease in dose also minimizes the hepatic and nephrotic load. The optimized batch of the formulation was subjected to comparative in vitro and in vivo evaluation. The tablet core composition is the primary influencer of the drug delivery fraction in a zero order, whereas the membrane characteristics control the drug release rate. In vivo pharmacokinetic studies revealed that the newly developed osmotic formulation has controlled zero-order release for 24h with a single dose of 450mg while the marketed formulation requires twice administration within 24h to maintain the plasma concentration in the therapeutic window. The pharmacokinetic study demonstrated that the developed formulation has the area under curve (AUC) of 58.415µgh/ml with single dose while the marketed formulation shows the AUC of about 37.903µgh/ml and 31.983µgh/ml for first and second dose, respectively. The large AUC demonstrates the extended release of drug with a single dose and effective plasma concentration. Hence, the developed formulation can be a promising option for the treatment of CMV retinitis with the minimum dose and dosing frequency.

Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate.

Topiramate (TPM) was an antiepileptic agent commonly used in clinical. Studies showed that an oral preparation of TPM with extended-release manner could bring some benefits for epileptics. In this paper, controlled release push-pull osmotic pump (PPOP) tablets of sparingly water-soluble TPM were successfully prepared. This bi-layer tablet core mainly consisted of sodium chloride as osmotic promoting agent and polyethylene oxide as suspending and pushing agents. The influences of osmotic agents, pushing agents and the compositions of coating membrane on TPM release profiles were evaluated. An optimal formulation of TPM-PPOP was obtained through single-factor experiments. In vitro release tests showed that the optimum formulation could release TPM at an approximate zero-order rate up to 8 h. Pharmacokinetic behaviors of TPM-PPOP tablets were evaluated and compared with the immediate release capsules after an oral single dose in beagle dogs. Pharmacokinetics results demonstrated that the TPM-PPOP tablet was able to provide a prolonged release of TPM with longer tmax and mean residence time. Lower fluctuations of drug plasma levels could also be achieved with TPM-PPOP tablets. These results suggested that sparely water-soluble drugs as TPM can be designed to PPOP for efficacy and safety use.

Zileuton compression coated tablets : formulation development and in vitro evaluation

In the present research work Zileuton tablets were formulated by employing compression coating technology. Initially the core tablets were prepared by using various concentrations of super disintegrates, the formulated core tablets were coated with the polymers by using compression coating technology. All the core and compress coated tablet formulations were subjected to various physical and chemical evaluation tests for core and compress coated tablets. The thickness, hardness and weight variation shown by all the tablet formulations were found within the official pharmacopoeial limits. In vitro release of Zileuton of core tablet formulations ZF5 showed faster drug release after 15 min. Faster drug release can be correlated with the high disintegration and friability observed in this study.

PREPARATION AND EVALUATION OF ACTIVE FILM COATING TABLET OF TENELIGLIPTIN HYDROBROMIDE HYDRATE WITH METFORMIN HYDROCHLORIDE FIXED DOSE COMBINATION

The aim of the present study was to formulate fixed-dose combination tablets of metformin hydrochloride and teneligliptin hydrobromide hydrate. The extended-release core tablet consisted of a seal coating over metformin and outer layer coated by teneligliptin for immediate release using perforated film coating equipment. The seal coating is necessary to prevent the contact between metformin and teneligliptin. 23 Full factorial design was planned to determine critical processing parameters like the effect of hydroxypropyl methyl cellulose and ethyl cellulose in seal coating, ratio of drug and polymer in the coating solution, and spray rate as variables with lower and higher level. Optimized (F9) batch prepared from the design space from experimental variable as seal coat ratio of 0.33, drug coat ratio of 2 with rate of spray 3 g mL-1, gave desired release pattern. The optimized formulation was subjected to in vivo kinetic studies using Wistar rats. Metformin 100 mg kg-1 was administered orally and blood was withdrawn at various time intervals to assess the kinetic parameters. The observed AUC and Cmax were found to be 260 ng*h mL-1, and 58.0 ng mL-1, respectively, and the time needed to reach Tmax was 6 h for metformin tablets.

Preparation and Characterization of Sumatriptan Timed Delivery System Using Combination of Natural and Synthetic Polymers

BACKGROUND: Pulsatile drug delivery systems are time-controlled dosage forms that release active pharmaceutical component after a predefined period in order to synchronize circadian cycle of illness. Migraine has a diurnal cycle, with episodes peaking between 6 a.m. and 8 a.m. Sumatriptan acts as a selective agonist for 5-Hydroxytryptamine1 (serotonin) receptors. Thus, it is an effective therapy for acute migraine episodes. AIM: The objective of the study is to create a time-controlled press-coated tablet containing two sumatriptan pulses. The first pulse demonstrated 100% active component release within 2 min, followed by the second sumatriptan pulse after just 5.5-h lag period. MATERIALS AND METHODS: We prepared eleven formulations for rapid dissolving core tablets and thirty-three formulations for press-coated tablet that were manufactured by direct compression technique. The third layer was then squeezed onto press-coated tablet to create a two-pulse-time-controlled system. The qualities of core tablets and coatings were examined using a variety of criteria. RESULTS: The formula F7 of core tablet was chosen because it had the lowest disintegration duration (8.8 s) with the quickest drug release within 2 min. In addition, formula C28 of the pectin-containing press-coated tablet: EC 100 mpa.s: HPMCK4M in concentrations of 20mg, 100 mg, and 80 mg were chosen as optimal coating layer. CONCLUSIONS: Utilizing pulsatile delivery system for sumatriptan is an effective strategy in resolving migraine attacks.

Pulsatile Chronotherapeutic Drug Delivery for Controlling Early Morning Surge in Blood Pressure; Effect of Coating on Eplerenone In-vitro, In-vivo Release and Urinary Na/K Ratio

The objective of the present study was to develop time delayed chronotherapeutic formulation of Eplerenone (Ep) to provide rapid drug release after a pre-determined lag time for the treatment of early morning hypertension. Cyclodextrin complexation was used to prepare fast release Ep core tablets. The developed core tablets were then coated with different rate-controlling polymers using compression coating technique. The developed tablets were evaluated for hardness, friability, drug content and swelling index. The in-vitro drug release was carried out to study the effect of different coating materials on drug release and lag time. Tablets selected for stability study were those showing lag time of 5-7 hours followed by complete drug release; F2, F3, F7, F8, and F12. The in-vivo study was carried out on tablets with the highest t90 as compared to commercial tablets after being administered to healthy human volunteers where plasma Ep and urinary Na/K ratio were determined. Results suggested that this approach was able to provide delayed release Ep formulations that will be useful for patients with morning surge in blood pressure.

Towards a Better Understanding of the Post-Gastric Behavior of Enteric-Coated Formulations

PurposeThe aim of our work was to develop a biorelevant dissolution method for a better understanding of the in vivo performance of delayed-release tablet formulations.MethodsThe typical pH profile and residence times in the stomach and small intestine were determined in fasted conditions based on the published results of swallowable monitoring devices. Then, a multi-stage pH shift dissolution method was developed by adding different amounts of phosphate-based buffer solutions to the initial hydrochloric acid solution. Because of the highly variable in vivo residence times in the stomach, two alternatives of the method were applied, modeling rapid and slow gastric emptying as well. This approach provided an opportunity to study the effect of the acidic treatment on post gastric release. Six enteric-coated low-dose acetylsalicylic acid (ASA) formulations including the reference Aspirin Protect were tested as a model compound. Moreover, the thickness of the coating of each formulation was investigated by scanning electron microscope.ResultsComparing the in vitro results to the known properties of the formulations, the new method was found to be more discriminative than the USP dissolution method. Ingredients affecting the in vitro dissolution, and thus probably the in vivo performance, were identified in both the tablet core and the coating of the tested formulations. The limited available in vivo data also indicated an increased predictivity.ConclusionOverall, the presented method may be an efficient tool to support the development of enteric coated generic formulations.Graphical abstract

Formulation and Evaluation of Colon Targeted Drug Delivery System

Purpose:The objective of the present study was to develop colon targeted drug delivery system of Metronidazole using guar gum as the carrier.Methods:Matrix tablets containing various proportions of guar gum were prepared by direct compression technique. Rapidly disintegrating Metronidazole core tablets were prepared and compression coated with guar gum and 20% of microcrystalline cellulose. The tablets were evaluated for hardness, thickness, drug uniformity and subjected to in vitro drug release studies under conditions mimicking mouth to colon transit. Results and Conclusions: The FTIR study indicates no possible interaction between Metronidazole and carriers. The tablets were found within the permissible limits for various physiological parameters. In vitro drug release studies in pH 6.8 phosphate buffer solution containing rat cecal contents have demonstrated the susceptibility of guar gum to the colonic bacterial enzyme action with consequent drug release. The pretreatment of rats orally with 1 ml of 2% w/v aqueous dispersion of guar gum for 7 d induced enzyme specifically acting on guar gum thereby increasing drug release. Dissolution studies were performed in 0.1N HCl for 2 h, in pH 7.4 buffer for 3 h and pH 6.8 up to 24 h. The cumulative percentage of drug release of Metronidazole after 24 h in pH 6.8 phosphatebuffers was found to be 98.51±0.02, 86.69±0.02, 84.55±0.04, 39.31±0.02, 24.60±0.02, 18.85±0.02 for formulation F1, F2, F3, F4, F5 and F6. It can be concluded that formulation F1 is considered a potential formulation for targeting the drug to the colon. The results showed that guar gum protects the drug from being release completely in the physiological environment of stomach and small intestine.©2022iGlobal Research and PublishingFoundation. All rights reserved.

Formulation design and Evaluation of Extended-Release Tablets of Oxybutynin for Effective Management of Overactive Bladder Syndrome

Overactive bladder syndrome (OAB) is a chronic condition with a composite of symptoms and has a significant negative impact on the physiological and psychological well-being of the patients. The present study is aimed at developing extended-release formulations of oxybutynin that is effective in reducing the side effects associated with the drug by maintaining a steady state concentration with minimal fluctuations in plasma drug concentration and thereby achieves improved patient compliance. The extended-release drug delivery of tablets can be achieved by preparing the matrix tablet of oxybutynin chloride with klucel HF in core tablet by wet granulation technique and functional coating with a combination of aquacoat ECD-30 and hypromellose E5 followed by film coating with opadry. For confirmation of compatibility, the pure drug and its physical mixtures were subjected to FTIR studies. All the formulations have shown acceptable limits in all precompression and post compression parameters. The in vitro release studies in 0.1N HCl and 6.8 phosphate buffer revealed that the optimized formulation F10 extend the release of the drug to 91% at 24 hours and the release profile was similar to the innovator’s product as revealed by the similarity factor study. The release kinetics study revealed that the release of the drug followed diffusion mechanism. Stability studies of the selected formulation tablets were carried out at 25°C ±2°C/60% RH±5% and 40°C ±2°C /75%±5% RH for different time period and all the parameter was within the limits after storage period. Thus the extended release matrix tablets of oxybutynin chloride developed in this study have immense potential to develop into a marketed product following the testing in animals and human volunteers.

Design and evaluation of a zero-order controlled release system based on pre-hydrated constant release area prepared by compression coating technology

The main aim of this research work was to develop and evaluate a drug delivery system with compression coating technology to control drug release at a constant rate. The compression coated tablets (CCTs) consist of the hydrophilic matrix core and the hydrophobic waxy coating. The presence of hydrophobic waxy coating could provide sufficient time for hydration of the core to prevent initial burst release. The mechanism research revealed that erosion was the main way of drug release and the releasing area was constant during the entire release process because the core tablet was located in the cup-shaped coating after one side cover was dropped at the lag time. This made the release behavior exhibit zero-order kinetics (R 2>0.99). The coating rupture strength and the core swelling force at the lag time influenced erosion rate thus affecting release rate. Different solubility of drugs (propranolol hydrochloride, melatonin, and nifedipine) was selected as model drugs and the properties of the prepared CCTs in terms of formulations and in vitro release were evaluated. The release rate was independent of solubility, medium pH, and osmotic pressure. This zero-order controlled system could be applied to both controlled drug delivery and chrono pharmaceutical drug delivery.

FORMULATION AND IN VITRO–IN VIVO PHARMACOKINETIC EVALUATION OF CARDIOVASCULAR DRUG-LOADED PULSATILE DRUG DELIVERY SYSTEMS

Objective: This study is to formulate Nebivolol into a Pulsatile liquid, solid composite compression coated tablet, which will delay the release of the drug in early morning hypertension conditions. Methods: The liquid, solid composite tablet was formulated and compressed with the ethylcellulose coating polymer. The percent in vitro drug release of the liquid solid composite compressed tablet was tested. Based on disintegration time and wetting time, the LCS2, LCS3, LSC6, LCS7 and LCS12 formulations were found to be the optimized solid-liquid compacts fast-dissolving core tablet formulations, which may be excellent candidates for further coating with polymer to transfer into press coated pulsatile tablet formulations. Coating the core tablet with varying ethyl cellulose concentrations resulted in five different formulations of the pulsatile press-coated tablet (CT1, CT2, CT3, CT4, CT5). In vitro drug release, in vitro release, kinetic studies, in vivo pharmacokinetic and stability tests were all performed for the prepared pulsatile press coated tablet. Results: CT3 tablets are coated with ethyl cellulose polymer, which shows maximum controlled drug release from the core tablet i.e. 96.34±1.2% at 8th h. It shows there was an efficient delay in drug release form core tablet i.e. up to 3 h, followed by the maximum amount of drug release of 96.34±2.4 at 8h. Which shows the core drug will be more efficiently protected from the gastric acid environment 1.2 pH, duodenal environment 4.0 pH and release drug only in the small intestine. Conclusion: According to the findings, CT3 Pulsatile press-coated tablet increased the bioavailability of Nebivolol by 3.11 percent.

Ph Responsive In-Vitro Drug Release Behavior of Poly (Malic Acid-Co-Butane-1,4-Diol-Co-Maleic Acid)

Four mixtures of malic acid and maleic acid in mole combinations (1.0+0.1), (1.0+0.2), (1.0+0.3), and (1.0+0.4) respectively were separately polymerized with one mole of butane 1,4-diol in Dean-Stark apparatus using xylene as the reaction medium. Among the synthesized co-polyesters, sample II had the highest molecular weight and it was selected for subsequent experiments. It was characterized by its IR-spectrum, solubility in common organic solvents, elemental analysis and hydrolytic degradation test. It was found from hydrolytic degradation test that the said polyester sample did not degrade or swell in acid medium but gradually degraded in basic medium. Because of having such pH responsive behavior it was tried as an enteric coating material on diclofenac sodium core tablets. In vitro drug release pattern of co-polyester coated samples matches with the British Pharmacopoeia standard drug release profile of enteric-coating material.

Development of Personalized Colonic Drug Delivery Systems Prepared by 3D-Printing Technology

Colonic drug delivery systems (CDDS) show several advantages for treatment of inflammatory bowel disease such as improving the clinical outcomes and minimizing side effects of corticosteroids. However, variation of the patient's gastrointestinal tract (GIT) in terms of transit time and pH causes the fluctuation of the drug releasing site in the GIT resulting in low therapeutic efficiency. Consequently, 3D-printing techniques have been applied for preparation of personalized colonic drug delivery systems in this study. Prednisolone was selected as a model drug and prepared in the form of a core tablet. Polylactic acid (PLA) and polyvinyl alcohol (PVA) were printed as a tablet housing and a drug control release plug, respectively. A two-factor full factorial model was utilized to design the experiment and partial least square regression (PLS) models were generated to reveal and predict drug release time of the system. From the results, only thickness of the PVA plug significantly affected the drug release at sampling times of 5, 6, 10, and 24 h. The relations between thickness of the plug and drug releases at 5, 6, and 10 h are quadratic but that of 24 h is linear. The relation between thickness of the plug and drug releases is quadratic. The drug could not be completely released in 24 h because the drug was entrapped by PVA gel. The search results show the possibility to utilize the PLS models to modify drug release time for individual patients. However, alteration of plug polymer is a suggestion to obtain complete drug release.

Regulatory 101: Bulk Holding Time Requirements

The FDA website provides guidance on various CGMP topics. The focus of this installment of Regulatory 101 is on the topic of bulk holding requirements. The question posed via the Q&A on CGMP’s is stated as “How long may a firm store in-process/intermediate powder blends and triturations, sustained-release pellets/beads, and tablet cores, absent separate stability studies, before using them in finished drug products?” Additional considerations are provided to further analyze this frequently asked question. Pharmaceutical products are manufactured to ensure safety, effectiveness, and quality for their intended use. As part of the product development process, stability studies are conducted to determine the appropriate shelf life for the product under specified storage conditions. These studies ensure all product specifications are met up to the assigned expiration date.

A Review on Tablet Dosage Form: Recent Advancements with Special Emphasis on Rapid Disintegrating Tablet

Tablets are the most commonly prescribed dosage form as offer a convenient form of drug administration provides dosage uniformity from tablet to tablet, stable over extended and diverse storage conditions, can be produced on high-speed compression, labelling, and packaging equipment. Advancements in technology and modification in standard compressed tablet are to achieve better acceptability as well as bioavailability. Various types of newer and more efficient tablets are developed to create a delivery system that is relatively simple to administration. In one sense osmotic pump systems are another type of membrane-controlled release drug delivery system and work in the following way. Drug is incorporated in a tablet core which is water soluble, and which will solubilize or suspend the drug in the presence of water. Also, a multi-layer tablet dosage form over a more conventional mono-layer tablet is useful. In FDDS Gastro retentive dosage form improves bioavailability, therapeutic efficacy and allows a reduction in the dose because of steady therapeutic levels of drug. The another system is MADDS Mucoadhesion is commonly used to describe an interaction between the mucin layer, which lines the entire GI tract, and a bio adhesive polymer, which could be natural or synthetic in origin. An ideal controlled drug delivery system is one which delivers the drugs at a predetermined rate, locally or systematically, for a specified period of time and an ideal targeted drug delivery system is the one which delivers the drugs only to its sites of action and not to the non-targeted organs or tissues. So, in this review article we will study the basic fundamentals of tablets their technologies, and types of systems with available marketed products of various dosage forms.